Quantitative Assessment of Inflammation in a Porcine Acute Terminal Ileitis Model: US with a Molecularly Targeted Contrast Agent

Huajun Wang, MD, PhD
Stephen A. Felt, DVM, MPH, DACLAM, DACVPM
Steven Machtaler, PhD
Ismayil Guracar, MSEE
Richard Luong, BVSc, DACVP
Thierry Bettinger, PhD
Lu Tian, PhD
Amelie M. Lutz, MD
Jürgen K. Willmann, MD

Purpose:
To evaluate the feasibility and reproducibility of ultrasonography (US) performed with dual-selectin–targeted contrast agent microbubbles (MBs) for assessment of inflammation in a porcine acute terminal ileitis model, with histologic findings as a reference standard.

Materials and Methods:
The study had institutional Animal Care and Use Committee approval. Acute terminal ileitis was established in 19 pigs; four pigs served as control pigs. The ileum was imaged with clinical-grade dual P- and E-selectin–targeted MBs (MB\text{Selectin}) at increasing doses (0.5, 1.0, 2.5, 5.0, 10, and 20 $\times$ $10^8$ MB per kilogram of body weight) and with control nontargeted MBs (MB\text{Control}). For reproducibility testing, examinations were repeated twice after the MB\text{Selectin} and MB\text{Control} injections. After imaging, scanned ileal segments were analyzed ex vivo both for inflammation grade (by using hematoxylin-eosin staining) and for expression of selectins (by using quantitative immunofluorescence analysis). Statistical analysis was performed by using the $t$ test, intraclass correlation coefficients (ICCs), and Spearman correlation analysis.

Results:
Imaging signal increased linearly ($P < .001$) between a dose of 0.5 and a dose of 3.0 $\times$ $10^8$ MB/kg and plateaued between a dose of 10 and a dose of 20 $\times$ $10^8$ MB/kg. Imaging signals were reproducible (ICC = 0.70), and administration of MB\text{Selectin} in acute ileitis resulted in a significantly higher ($P < .001$) imaging signal compared with that in control ileum and MB\text{Control}. Ex vivo histologic grades of inflammation correlated well with in vivo US signal ($p = 0.79$), and expression levels of both P-selectin (37.4% $\pm$ 14.7 [standard deviation] of vessels positive; $P < .001$) and E-selectin (31.2% $\pm$ 25.7) in vessels in the bowel wall of segments with ileitis were higher than in control ileum (5.1% $\pm$ 3.7 for P-selectin and 4.8% $\pm$ 2.3 for E-selectin).

Conclusion:
Quantitative measurements of inflammation obtained by using dual-selectin–targeted US are reproducible and correlate well with the extent of inflammation at histologic examination in a porcine acute ileitis model as a next step toward clinical translation.

Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights.
Inflammatory bowel disease (IBD) is a group of chronic relapsing disorders, including Crohn disease and ulcerative colitis, with inflammatory changes in the small and large bowel (1,2). Approximately 1.4 million patients are affected in the United States, and the global incidence of the disease is increasing (3). Current therapies for IBD with immunosuppressants and immunomodulators are not disease specific and may have major side effects (2,4). Therefore, ongoing research explores inexpensive, widely available, safe, and noninvasive methods for the quantitative assessment of disease extent that allow better individualization of treatment regimens through earlier differentiation of nonresponders from responders and minimization of drug doses in patients responding to a certain treatment (5). Currently, there is no single test available that fulfills these requirements.

Ultrasonography (US) is an accessible, noninvasive, and safe imaging modality. In particular, in children and young adults with good acoustic windows, US is considered to be one of the first-line imaging modalities for assessing bowel diseases. In IBD, after the diagnosis is confirmed with endoscopy and histologic examination and the extent of bowel involvement is assessed by using magnetic resonance imaging or computed tomographic (CT) enterography, US can be used as a complementary, noninvasive, and relatively inexpensive test to longitudinally monitor inflammation and to differentiate responders from nonresponders early in treatment without radiation exposure. However, the accuracy and reproducibility of current US technology in the quantification of inflammation are limited (6,7).

Molecular imaging with US utilizes contrast agent microbubbles (MBs) that have been modified to enable molecular targeting to proteins upregulated in the inflamed vasculature. This technique has been used to quantify inflammation in small-animal models of IBD (8,9). Leveraging the natural pathway of leukocyte rolling on inflamed vascular endothelial cells, a clinically translatable, dual-targeted contrast agent (10,11) specific for the leukocyte adhesion molecules P- and E-selectin has been shown to enable accurate quantification of inflammation in a murine model of chemically induced colitis (12). Furthermore, in an intra-animal cross-modality comparison (12), dual-selectin–targeted US signal correlated well quantitatively with fluorodeoxyglucose uptake at positron emission tomography/CT in murine colitis. These data suggest that US with a dual-selectin–targeted contrast agent may be further developed as a quantitative tool for monitoring inflammation in IBD (8,9).

The purpose of our study was to evaluate the feasibility and reproducibility of US with dual-selectin–targeted MBs for assessment of inflammation in a porcine acute terminal ileitis model, with histologic findings as a reference standard.

**Materials and Methods**

Bracco Suisse (Geneva, Switzerland) provided the clinically translatable contrast agent used in this study. The authors who were not employees of Bracco Suisse (H.W., S.A.F., S.M., I.G., R.L., I.T., A.M.L., J.K.W.) had control over inclusion of any data and information that might have presented a conflict of interest for the author who was an employee of Bracco Suisse (T.B.).

**Animals**

This study was approved by the institutional Animal Care and Use Committee of Stanford University. Twenty-three 11–13-week-old female pigs (Yorkshire; Pork Power Farms, Turlock, Calif; mean weight, 31 kg; range, 25–37 kg) were used in this study. All pigs were housed in an Association for Assessment and Accreditation of Laboratory Animal Care–accredited and U.S. Department of Agriculture–registered facility. Pigs were fed a commercially prepared balanced ration (Nature’s Match Sow and Pig Complete; Purina Mills, St Louis, Mo) ad libitum, with exception of the

**Materials and Methods**

Bracco Suisse (Geneva, Switzerland) provided the clinically translatable contrast agent used in this study. The authors who were not employees of Bracco Suisse (H.W., S.A.F., S.M., I.G., R.L., I.T., A.M.L., J.K.W.) had control over inclusion of any data and information that might have presented a conflict of interest for the author who was an employee of Bracco Suisse (T.B.).

**Animals**

This study was approved by the institutional Animal Care and Use Committee of Stanford University. Twenty-three 11–13-week-old female pigs (Yorkshire; Pork Power Farms, Turlock, Calif; mean weight, 31 kg; range, 25–37 kg) were used in this study. All pigs were housed in an Association for Assessment and Accreditation of Laboratory Animal Care–accredited and U.S. Department of Agriculture–registered facility. Pigs were fed a commercially prepared balanced ration (Nature’s Match Sow and Pig Complete; Purina Mills, St Louis, Mo) ad libitum, with exception of the

**Materials and Methods**

Bracco Suisse (Geneva, Switzerland) provided the clinically translatable contrast agent used in this study. The authors who were not employees of Bracco Suisse (H.W., S.A.F., S.M., I.G., R.L., I.T., A.M.L., J.K.W.) had control over inclusion of any data and information that might have presented a conflict of interest for the author who was an employee of Bracco Suisse (T.B.).

**Animals**

This study was approved by the institutional Animal Care and Use Committee of Stanford University. Twenty-three 11–13-week-old female pigs (Yorkshire; Pork Power Farms, Turlock, Calif; mean weight, 31 kg; range, 25–37 kg) were used in this study. All pigs were housed in an Association for Assessment and Accreditation of Laboratory Animal Care–accredited and U.S. Department of Agriculture–registered facility. Pigs were fed a commercially prepared balanced ration (Nature’s Match Sow and Pig Complete; Purina Mills, St Louis, Mo) ad libitum, with exception of the

**Materials and Methods**

Bracco Suisse (Geneva, Switzerland) provided the clinically translatable contrast agent used in this study. The authors who were not employees of Bracco Suisse (H.W., S.A.F., S.M., I.G., R.L., I.T., A.M.L., J.K.W.) had control over inclusion of any data and information that might have presented a conflict of interest for the author who was an employee of Bracco Suisse (T.B.).

**Animals**

This study was approved by the institutional Animal Care and Use Committee of Stanford University. Twenty-three 11–13-week-old female pigs (Yorkshire; Pork Power Farms, Turlock, Calif; mean weight, 31 kg; range, 25–37 kg) were used in this study. All pigs were housed in an Association for Assessment and Accreditation of Laboratory Animal Care–accredited and U.S. Department of Agriculture–registered facility. Pigs were fed a commercially prepared balanced ration (Nature’s Match Sow and Pig Complete; Purina Mills, St Louis, Mo) ad libitum, with exception of the

**Materials and Methods**

Bracco Suisse (Geneva, Switzerland) provided the clinically translatable contrast agent used in this study. The authors who were not employees of Bracco Suisse (H.W., S.A.F., S.M., I.G., R.L., I.T., A.M.L., J.K.W.) had control over inclusion of any data and information that might have presented a conflict of interest for the author who was an employee of Bracco Suisse (T.B.).

**Animals**

This study was approved by the institutional Animal Care and Use Committee of Stanford University. Twenty-three 11–13-week-old female pigs (Yorkshire; Pork Power Farms, Turlock, Calif; mean weight, 31 kg; range, 25–37 kg) were used in this study. All pigs were housed in an Association for Assessment and Accreditation of Laboratory Animal Care–accredited and U.S. Department of Agriculture–registered facility. Pigs were fed a commercially prepared balanced ration (Nature’s Match Sow and Pig Complete; Purina Mills, St Louis, Mo) ad libitum, with exception of the
times 12 hours prior to surgery and 12 hours prior to US. Water was made available at all times.

Figure 1 summarizes the overall study design, which included a dose-escalation study of increasing contrast agent doses in a subgroup of five animals, a reproducibility study in a subgroup of four animals, and quantitative correlation of selectin-targeted US with histologic findings in all 23 animals.

The acute terminal ileitis model in pigs (Fig E1 [online]) and the preparation of dual-selectin–targeted

Figure 1: A–C, Overview of experimental design for in vivo dual-selectin–targeted US in pigs shows, A, the testing of different MB doses, B, the testing for reproducibility, and, C, the correlation of imaging findings with pathologic findings. MB

Control = control MBs, MB

Selectin = dual-selectin–targeted MBs, TNBS = 2, 4, 6-trinitrobenzene sulfonic acid. (For more details on the animal model, please see Appendix E1 [online].)
MBs are described in Appendix E1 (online).

**In Vivo US Protocol**

All 23 pigs were anesthetized as described in Appendix E1 (online) and were placed in the supine position. One hour before US scanning, 2 L of a highly diluted barium sulfate suspension (VoluMent; E-Z-Em, Lake Success, NY) was administered through a nasogastric tube placed into the stomach to improve small bowel distention and to minimize intraluminal air, according to standard protocols for clinical cross-sectional small-bowel imaging (13–15). Pigs were premedicated with acetylsalicylic acid (Aspirin; Wedgewood, Swedesboro, NJ) administered either orally (3.5 mg per kilogram of body weight, every 12 hours beginning 24 hours prior to US; \( n = 12 \)) or intravenously (3.5 mg/kg; 5 minutes prior to intravenous contrast agent injection; \( n = 11 \)) as previously described (16–19).

In all pigs, imaging was performed by an abdominal radiologist (J.K.W., with 14 years of experience) using a clinical US scanner (Acuson Sequoia 512; Siemens Healthcare, Malvern, Pa) and a 15L8W clinical transducer 48 hours after the induction of ileitis. In a subgroup of eight pigs, imaging was also performed 1 hour after induction of ileitis to assess whether selectin-targeted US allows the detection of early changes after inflammation induction. In these eight animals, the same segments of ileum before inflammation induction served as intra-animal control tissue, and the segment was scanned again at 48 hours.

First, the terminal ileum was identified in brightness mode. Transverse selectin-targeted US data sets of acute ileitis were then acquired in contrast pulse sequencing mode (center frequency, 7 MHz; lateral and axial resolution, 200 μm each; transmit power, −18 dB; mechanical index, 0.23; and dynamic range, 80 dB) 4 minutes after intravenous bolus injection of \( 5 \times 10^8 \) kg MB\(_{\text{Selectin}} \) or MB\(_{\text{Control}} \) through a 20-22-gauge intravenous catheter placed in the auricular vein and followed by a 10-mL saline chaser. Four minutes after the injection of the contrast agents, 160 imaging frames were acquired, which detected signals from both molecularly attached targeted MBs and freely circulating MBs. Then, a 5-second destruction pulse (full transmit power; mechanical index, 1.9) was applied to destroy all MBs in the same field of view. After the destruction pulse, another 160 imaging frames were acquired in the same imaging plane to obtain the signal from freely circulating MBs only. The injection order of MB\(_{\text{Selectin}} \) or MB\(_{\text{Control}} \) was randomized in all pigs, and a pause of at least 30 minutes was allowed between injections to allow the clearance of MBs from the preceding injection. To maximize intra-animal data acquisition and to minimize the overall number of animals needed, we imaged between one and five locations (at least 1 cm apart) of either control or inflamed bowel segments per pig. A total of 34 bowel segments with moderate-to-severe ileitis, eight segments with mild ileitis (proximal ileum segments), and 15 segments with no ileitis (normal control bowel) were scanned.

**Dose-Escalation Study of Selectin-targeted MBs in Acute Terminal Ileitis**

In five pigs with moderate-to-severe acute terminal ileitis, an intra-animal dose-escalation study of the dual-selectin–targeted contrast agent was performed. For this purpose, US with the protocol described above was performed after intravenous injection of increasing doses of MB\(_{\text{Selectin}} \) (0.5, 1.0, 2.5, 5.0, 10, and \( 20 \times 10^8 \) kg) with a waiting time of at least 30 minutes between each injection to allow clearance of all MBs from preceding injections.

**Reproducibility of Selectin-targeted US**

To evaluate the reproducibility of dual-selectin-targeted US, an additional three animals with moderate-to-severe acute terminal ileitis and one control animal were imaged twice, consecutively, after both MB\(_{\text{Selectin}} \) and MB\(_{\text{Control}} \) injections (5.0 \( \times 10^8 \) kg each) in randomized order in the same session by using the imaging protocol described above. Again, there was a pause of at least 30 minutes between the different injections.

**Image Analysis**

All US data sets were analyzed offline by one reader (H.W.; a radiologist with 3 years of experience) in a random order using software created in-house with MatLab, version 7.01 R14 (MathWorks, Natick, Mass). The reader was blinded to the bowel segment scanned (ileitis vs normal control bowel), to the MB types (MB\(_{\text{Selectin}} \) vs MB\(_{\text{Control}} \)), and to the MB doses. A region of interest (ROI) (mean size, \( 127 \) mm\(^2 \); range, 72–236 mm\(^2 \)) was drawn over the wall of the ileum on transverse images. The magnitude of the imaging signal was calculated as the intensity ratio, defined as the ratio between the average linearized imaging signal amplitude before destruction and the average linearized imaging signal amplitude within the ROI after destruction. This parameter is not influenced by combinations of system settings (eg, gain, which can vary slightly among animals) and the attenuation of acoustic waves through tissue (which can also vary among pigs because of their different body weights).

**Ex Vivo Analysis of Ileum Tissue**

For each bowel segment imaged, the US locations were marked on the skin of each pig by using a waterproof marker (Sharpie, Oak Brook, Ill) to ensure that about the same area of the bowel segment could be correlated between US and histologic examination. Immediately after US, all pigs were sacrificed by means of intravenous injection of pentobarbital sodium (Bue\( \text{thanasiaD}\); Schering-Plough Animal Health, Union, NJ), and the imaged bowel segments were harvested for ex vivo analysis, including hematoxylin-eosin staining (for inflammation grading) and immunofluorescence staining (for assessment of P- and E-selectin expression levels). Details of staining are in Appendix E1 (online).
MOLECULAR IMAGING: US of Inflammation in an Ileitis Model with a Molecularly Targeted Contrast Agent

Wang et al

Figure 2

(a) Graph summarizes quantitative US signal intensities (represented as signal intensity ratios) observed in five pigs with acute terminal ileitis with increasing doses (0.5, 1.0, 2.5, 5.0, 10, and $2 \times 10^8$ MB/kg) of dual-selectin–targeted contrast MBs (MB_{Selectin}). Error bars = standard deviations, b.w. = body weight.

(b) Representative transverse US images obtained six times in approximately the same location of an inflamed ileum segment (arrows) in one pig show increasing imaging signal (overlaid in red onto the anatomic B-mode images) with increasing MB_{Selectin} doses, with the signal plateauing between a dose of 10 and a dose of $2 \times 10^8$ MB/kg. Note that US with MB_{Selectin} depicts inflammation not only in the bowel wall but also in mesenteric fat adjacent to the ileum. The different US scans were each separated by a 30-minute pause to allow contrast agent clearance.

Statistical Analysis

To assess the reproducibility of selectin-targeted US, we calculated intraclass correlation coefficients (ICCs) along with 95% confidence intervals. An ICC of 0–0.20 suggested no agreement; an ICC of 0.21–0.40, poor agreement; an ICC of 0.41–0.60, moderate agreement; an ICC of 0.61–0.80, good agreement; and an ICC of greater than 0.80, excellent agreement (20). The random-effects model was used for comparisons in multiple groups (control ileum, ileitis at 1 hour, and ileitis at 48 hours). A pig-specific random intercept was used to account for within-pig correlations. Similarly, the trend association between dose level and imaging signal was calculated with linear mixed-effect regression, while accounting for the within-subject correlation by using a random intercept. The signal intensity at different dose levels was estimated, and the incremental value of dose escalation was used to select the optimal dose. Specifically, the improved signal intensity per units of increased dose was estimated from 0.5 to 1.0, from 1.0 to 2.5, from 2.5 to 5.0, from 5.0 to 10, and from 10 to $2 \times 10^8$ MB/kg. For assessing associations between US signals and inflammation grades at hematoxylin-eosin staining, the Spearman correlation coefficient was estimated, and the corresponding $P$ values were obtained by using the Fisher transformation. All statistical analyses were performed with statistical software (R software, version 2.10.1; R Foundation for Statistical Computing, Vienna, Austria). The significance level was set at .05.

Results

Dose-Escalation Study of Selectin-targeted MBs

In the subgroup of pigs imaged after administration of different doses of MB_{Selectin}, overall in vivo imaging signal intensities significantly ($P < .001$) increased with higher contrast agent doses in an approximately linear fashion up to a dose of $5.0 \times 10^8$ MB/kg (Fig 2). Signal intensities did not significantly further increase when the dose was increased from 10 to $20 \times 10^8$/kg ($P = .20$), suggesting plateauing of the imaging signal at higher doses.

Reproducibility of Selectin-targeted US

Overall, the reproducibility of selectin-targeted molecular contrast enhancement after two consecutive contrast agent injections was good (ICC = 0.70; 95% confidence interval: 0.50, 0.83), and US signal was not significantly different ($P = .27$) after two consecutive injections.

In Vivo Selectin-targeted US

In normal ileum in control animals, the mean imaging signal ratios were only minimal after administration of both MB_{Control} (1.1 ± 0.1 [standard deviation]) and MB_{Selectin} (1.2 ± 0.1), and the imaging signal ratios were not significantly different when either MB type was used ($P = .18$) (Tables 1, 2; Figs 3, 4). One hour after the induction of
inflammation, the dual-selectin–targeted contrast agent–enhanced US imaging signal ratio (1.9 ± 0.4) was significantly increased (P = .01) compared with that in baseline normal ileum in the same animals. Imaging signal ratios (mean, 3.0 ± 1.3) further significantly increased (P = .03) at 48 hours compared with those in normal ileum in control animals (Tables 1, 2; Figs 3, 4). Administration of MB Control resulted in significantly lower imaging signal ratios in the bowel wall in both mildly inflamed bowel (1.1 ± 0.1; P = .003) and moderately to severely inflamed ileum (1.2 ± 0.3; P < .001) (Tables 1, 2; Figs 3, 4).

Ex Vivo Analysis

Histologic examination confirmed the presence of moderate-to-severe inflammation in all segments that were directly exposed to TNBS/ethanol (mean inflammation score, 3.2 ± 0.8; range, 2–4; Fig 3). Histologic inflammation grades were significantly lower in segments proximal to the directly exposed segments, with, on average, mild inflammation (mean score, 1.5 ± 0.8; range, 1–4; P = .03). In control animals without TNBS/ethanol exposure, there was background neutrophil inflammation only (1.0 ± 0; P < .001). Overall, there was good correlation between inflammation grades as assessed at histologic examination and selectin-targeted US signal (r = 0.79, P < .001).

Consistent with the US findings, quantitative immunofluorescent staining of the ileum showed that both P-selectin (37.4% ± 14.7 of vessels positive; P < .001) and E-selectin (31.2% ± 25.7) expression levels in vessels in the bowel wall of ileitis segments were higher than those in control ileum (5.1% ± 3.7 for P-selectin and 4.8% ± 2.3 for E-selectin). Selectin-positive vessels were often observed in close proximity to neutrophils present in the submucosa and the base of the mucosa (Fig E2 [online]).

Discussion

Our study results show that dual-selectin–targeted US using a clinical US system and clinical-grade contrast agent MBs can be translated to a large-animal porcine acute terminal ileitis model and that US findings correlate well with different grades of inflammation in the bowel wall at reference-standard histologic examination, suggesting that this imaging approach could become a useful tool for noninvasive monitoring of inflammation in IBD.

Pigs are increasingly being recognized as important large-animal models for IBD (21–24). We modified published protocols of chemically induced ileitis using TNBS/ethanol installation (22,23) to create a reproducible and well-tolerated porcine terminal ileitis model. In this model, ethanol breaks the physical barrier of the intestine, allowing TNBS to haptenize intestinal autologous or microbiota proteins. This results in a T-cell–dependent mucosal immune response and transmural infiltration of neutrophils (10,25). We observed that the volume of ethanol can be substantially reduced to 0.8 mL (compared with 40 mL, as published previously [22,23]), which caused moderate-to-severe TNBS-mediated inflammation with minimal discomfort to the animals. Another detail worth noting is the need to premedicate pigs with aspirin, indomethacin, or a specific thromboxane receptor blocker before injecting lipid-based particles such as MBs (16–18), because pigs have abundant intrapulmonary macrophages (26,27). These macrophages rapidly clear intravenously injected particles and immediately release substances such as vasoconstrictor thromboxane A2, with subsequent pulmonary arterial hypertension, systemic

Table 1

<table>
<thead>
<tr>
<th>Type of Bowel</th>
<th>MB Control</th>
<th>MB Selectin</th>
<th>PValue (MB Control vs MB Selectin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control ileum</td>
<td>1.1 ± 0.1</td>
<td>1.2 ± 0.1</td>
<td>.18</td>
</tr>
<tr>
<td>Ileitis at 1 hour</td>
<td></td>
<td>1.9 ± 0.4</td>
<td>.01</td>
</tr>
<tr>
<td>Mild ileitis at 48 hours</td>
<td>1.1 ± 0.1</td>
<td>1.6 ± 0.3</td>
<td>.003</td>
</tr>
<tr>
<td>Moderate-to-severe ileitis at 48 hours</td>
<td>1.2 ± 0.3</td>
<td>3.0 ± 1.3</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Note.—Data are means ± standard deviations, with ranges in parentheses. The same dose (5.0 × 10² MB/kg) was used for both MB Selectin and MB Control. Imaging signal from attached MBs was calculated as the intensity ratio, defined as the ratio between the average linearized imaging signal amplitude before destruction and the that after destruction within the region of interest. Note that US studies at 1 hour were performed in intra-animal comparison experiments, and histologic inflammation grades were therefore not available because the same bowel segment was also scanned at 48 hours.

Table 2

<table>
<thead>
<tr>
<th>Study Group and Comparison</th>
<th>PValue</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB Control</td>
<td></td>
</tr>
<tr>
<td>Control ileum vs mild ileitis</td>
<td>.29</td>
</tr>
<tr>
<td>Control ileum vs moderate-to-severe ileitis</td>
<td>.30</td>
</tr>
<tr>
<td>Control ileum vs mild ileitis</td>
<td>.24</td>
</tr>
<tr>
<td>MB Selectin</td>
<td></td>
</tr>
<tr>
<td>Control ileum vs ileitis at 1 hour</td>
<td>.01</td>
</tr>
<tr>
<td>Ileitis at 1 hour vs moderate-to-severe ileitis</td>
<td>.002</td>
</tr>
<tr>
<td>Control ileum vs mild ileitis</td>
<td>.27</td>
</tr>
<tr>
<td>Control ileum vs moderate-to-severe ileitis</td>
<td>.03</td>
</tr>
<tr>
<td>Mild ileitis vs moderate-to-severe ileitis</td>
<td>.02</td>
</tr>
</tbody>
</table>

Note.—The same dose (5.0 × 10² MB/kg) was used for both MB Selectin and MB Control. Overall, the imaging signal ratios with MB Control among the groups of control ileum, mild ileitis at 48 hours, and moderate-to-severe ileitis at 48 hours were not significantly different (P = .28), while the imaging signal ratios with MB Selectin were significantly different among the groups of control ileum, ileitis at 1 hour, mild ileitis at 48 hours, and moderate-to-severe ileitis at 48 hours (P < .001).
hypotension, and decreased cardiac output (19,28).

After optimizing the animal model, we performed a dose-escalation study and showed in intra-animal comparisons that imaging signal increased in a dose-dependent linear manner up to a dose of MB\textsubscript{Selectin} of $5.0 \times 10^{8}$/kg and then leveled off between a dose of 10 and a dose of $20 \times 10^{8}$/kg. A possible explanation for the signal plateauing at higher doses includes steric hindrance of further MB binding and the masking of still-available receptor binding sites by already attached MBs because of their relatively large size. For all subsequent experiments, we chose a dose of $5.0 \times 10^{8}$/kg, which allowed the measurement of different selectin expression levels in different inflammation grades without a signal plateauing effect. This dose corresponds to 2.6 µL injected gas per kilogram and is very similar to the U.S. Food and Drug Administration–recommended dose for a nontargeted contrast agent MB used in patients in the United States. The recommended dose of the nontargeted perflutren lipid MB Definity (Lantheus Medical Imaging, North Billerica, Mass) is 1.5 µL/kg (corresponding to 10-µL/kg MB suspension) per bolus injection in human patients [29]). At this dose, US was well reproducible in consecutive examinations, and the magnitude of in vivo US signal correlated well with ex vivo histologic findings over a spectrum of inflammation grades.

We also tested how early after an inflammation stimulus a substantial increase in the dual-selectin–targeted US signal can be measured. We observed that as early as 1 hour after acute terminal ileitis induction, US signal was significantly increased. This rapid increase is likely due to the rapid expression of P-selectin on vascular endothelial cells following an acute inflammation stimulus, with efficient attachment of the dual-selectin–targeted MBs to the P-selectin receptor (30,31). P-selectin is contained in Weibel-Palade bodies within vascular endothelial cells and is immediately released, with subsequent appearance on the cell surface within only a few minutes of the stimulus (30,31). This rapid surface expression makes this protein a promising molecular target for imaging hyperacute inflammation, which could be further exploited in, for example, future imaging of transient ischemic events in the bowel. The second target of the MB, E-selectin, is under transcriptional control, and its expression on vascular endothelial cells can be measured approximately 2 hours after acute stimulation (30,32,33). In our study, US signal substantially increased...
from 1 hour to 48 hours after acute ileitis induction, which is likely a result of increased expression levels of both selectins at the later time point with increased attachment of MBs to both selectins. Immunofluorescence staining at 48 hours confirmed upregulation of both selectins in inflamed bowel tissue. Similar to previous results in mice (12), both selectins were expressed in the capillaries of the mucosa and submucosa in inflamed ileum in pigs.

We acknowledge the following limitations of our study: First, the porcine model was adapted from rodent models (12,34). Although histologic examination, acute TNBS/ethanol exposure resulted in a phenotype that resembled acute inflammation in patients with IBD, the acute nature of the model did not reflect the chronicity of the disease, which often results in acute-on-chronic changes. Second, in this proof-of-principle study, the imaged bowel was attached to the abdominal wall to allow reliable quantitative comparison between in vivo imaging findings and ex vivo histologic findings. Future studies are warranted to assess how US allows quantification of inflammation in nonattached bowel segments. Third (according to the company’s information), the only commercially available antihuman E-selectin antibody with cross-reactivity against pigs can also reveal human and pig P-selectin. Therefore, the quantitative immunofluorescent staining results for E-selectin may be in part confounded by concurrent P-selectin binding of the antibody. Fourth, we did not assess whether US allows accurate quantification of inflammation longitudinally (eg, during anti-inflammatory treatment).

**Practical applications:** The results of our study suggest that selectin-targeted US with dual-selectin–targeted MBs can be translated from small- to large-animal imaging in an acute terminal ileitis model in pigs with current clinical US equipment. This is a critical further step toward future clinical translation of this imaging approach for accurate and objective quantification of inflammation in the abdomen. Because US is widely accessible, relatively inexpensive, and does not involve ionizing radiation, selectin-targeted US may have substantial future clinical utility as a complementary imaging modality for diagnosis and treatment of patients with IBD.

**Disclosures of Conflicts of Interest:** H.W. disclosed no relevant relationships. S.A.F. disclosed no relevant relationships. S.M. disclosed no relevant relationships. I.G. Activities related to the present article: none to disclose. Activities not related to the present article: is an employee of Siemens Healthcare. Other relationships: none to disclose. R.L. disclosed no relevant relationships. T.B. Activities related to the present article: none to disclose. Activities not related to the present article: is an employee of Braun Suisse (since 2001). Other relationships: none to disclose. L.T. disclosed no relevant relationships. A.M.L. disclosed no relevant relationships. J.K.W. Activities related to the present article: none to disclose. Activities not related to the present article: is a consultant for Triple Ring Technologies and Bracco; institution has received grants from Siemens, Philips, and GE. Other relationships: none to disclose.

**References**


binding to both E- and P-selectin in different species. Invest Radiol 2012;47(9):516–523.


